

Quantikine[®] ELISA

Human IL-6 Immunoassay

Catalog Number D6050

S6050

PD6050

For the quantitative determination of human Interleukin 6 (IL-6) concentrations in cell culture supernates, serum, and plasma.

Note: The standard reconstitution method has changed. Please read this package insert in its entirety before using this product.

This package insert must be read in its entirety before using this product.
For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS

SECTION	PAGE
INTRODUCTION	1
PRINCIPLE OF THE ASSAY	2
LIMITATIONS OF THE PROCEDURE	2
TECHNICAL HINTS	2
MATERIALS PROVIDED & STORAGE CONDITIONS	3
OTHER SUPPLIES REQUIRED	4
PRECAUTIONS	4
SAMPLE COLLECTION & STORAGE	4
REAGENT PREPARATION	5
ASSAY PROCEDURE	6
CALCULATION OF RESULTS	7
TYPICAL DATA	7
PRECISION	8
RECOVERY	8
SENSITIVITY	8
LINEARITY	9
CALIBRATION	9
SAMPLE VALUES	9
SPECIFICITY	10
REFERENCES	11
PLATE LAYOUT	12

MANUFACTURED AND DISTRIBUTED BY:

USA & Canada | R&D Systems, Inc.

614 McKinley Place NE, Minneapolis, MN 55413, USA
TEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656-4400
E-MAIL: info@RnDSystems.com

DISTRIBUTED BY:

UK & Europe | R&D Systems Europe, Ltd.

19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UK
TEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420
E-MAIL: info@RnDSystems.co.uk

INTRODUCTION

Interleukin 6 (IL-6) is a pleiotropic, α -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature human IL-6 is 183 amino acids (aa) in length and shares 39% aa sequence identity with mouse and rat IL-6 (6). Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (7-10). Cells known to express IL-6 include CD8⁺ T cells, fibroblasts, synoviocytes, adipocytes, osteoblasts, megakaryocytes, endothelial cells (under the influence of endothelins), sympathetic neurons, cerebral cortex neurons, adrenal medulla chromaffin cells, retinal pigment cells, mast cells, keratinocytes, Langerhans cells, fetal and adult astrocytes, neutrophils, monocytes, eosinophils, colonic epithelial cells, B1 B cells and pancreatic islet beta cells (2, 11-33). IL-6 production is generally correlated with cell activation and is normally kept in control by glucocorticoids, catecholamines, and secondary sex steroids (2). Normal human circulating IL-6 is in the 1 pg/mL range, with slight elevations during the menstrual cycle, modest elevations in certain cancers, and large elevations after surgery (34-38).

IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R α) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R α , triggering IL-6 R α association with gp130 and gp130 dimerization (39). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (40). Soluble forms of IL-6 R α are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R α elicit responses from gp130-expressing cells that lack cell surface IL-6 R α (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R α is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R α but not from other cytokines that use gp130 as a co-receptor (5, 41).

IL-6, along with TNF- α and IL-1, drives the acute inflammatory response. IL-6 is almost solely responsible for fever and the acute phase response in the liver, and it is important in the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in conditions such as obesity, insulin resistance, inflammatory bowel disease, arthritis, and sepsis (2, 5). IL-6 modulates bone resorption and is a major effector of inflammatory joint destruction in rheumatoid arthritis through its promotion of Th17 cell development and activity (1). It contributes to atherosclerotic plaque development and destabilization as well as the development of inflammation-associated carcinogenesis (1, 2). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of memory B cells and plasma cells (42).

The Quantikine Human IL-6 Immunoassay is a 4.5 hour solid phase immunoassay designed to measure IL-6 in cell culture supernates, serum, and plasma. It contains *E. coli*-expressed recombinant human IL-6, and antibodies raised against the recombinant protein. Natural human IL-6 showed dose-response curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that this kit can be used to determine relative levels of natural human IL-6.

It has been observed in our laboratories that the measurement of IL-6 is insensitive to the addition of the recombinant form of the IL-6 soluble receptor. Therefore it is probable that experimental sample measurements reflect the total amount of IL-6 present, i.e., the total amount of free IL-6 plus the amount of IL-6 initially bound to soluble receptors, if any are present in the samples. High levels of high-affinity autoantibodies to IL-6 in the serum of some blood donors have been reported (36, 37). Such autoantibodies have the potential to interfere with the measurement of IL-6 by ELISA immunoassays.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human IL-6 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-6 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for human IL-6 is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of IL-6 bound in the initial step. The color development is stopped and the intensity of the color is measured.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- It is important that the Calibrator Diluent selected for the standard curve be consistent with the samples being assayed.
- If samples generate values higher than the highest standard, dilute the samples with the appropriate Calibrator Diluent and repeat the assay. If cell culture supernate samples require larger dilutions, perform an intermediate dilution with culture media and the final dilution with the appropriate Calibrator Diluent.
- Any variation in standard diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
- Variations in sample collection, processing, and storage may cause sample value differences.
- This assay is designed to eliminate interference by other factors present in biological samples. Until all factors have been tested in the Quantikine Immunoassay, the possibility of interference cannot be excluded.

TECHNICAL HINTS

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.
- Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.

MATERIALS PROVIDED & STORAGE CONDITIONS

Store the unopened kit at 2-8 °C. Do not use past kit expiration date.

PART	PART #	CATALOG # D6050	CATALOG # S6050	DESCRIPTION	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Human IL-6 Microplate	890045	1 plate	6 plates	96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody specific for human IL-6.	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of zip-seal. May be stored for up to 1 month at 2-8 °C.*
Human IL-6 Standard	890047	1 vial	6 vials	Recombinant human IL-6 in a buffered protein base with preservatives; lyophilized. <i>Refer to the vial label for reconstitution volume.</i>	Aliquot and store for up to 1 month at ≤ -20 °C in a manual defrost freezer.* Avoid repeated freeze-thaw cycles.
Human IL-6 Conjugate	890046	1 vial	6 vials	21 mL/vial of polyclonal antibody specific for human IL-6 conjugated to horseradish peroxidase with preservatives.	May be stored for up to 1 month at 2-8 °C.*
Assay Diluent RD1W	895117	1 vial	6 vials	11 mL/vial of a buffered protein base with preservatives.	
Calibrator Diluent RD5T	895175	1 vial	6 vials	21 mL/vial of a buffered protein base with preservatives. <i>For cell culture supernate samples.</i>	
Calibrator Diluent RD6F	895018	1 vial	6 vials	21 mL/vial of animal serum with preservatives. <i>For serum/plasma samples.</i>	
Wash Buffer Concentrate	895003	1 vial	6 vials	21 mL/vial of a 25-fold concentrated solution of buffered surfactant with preservative. <i>May turn yellow over time.</i>	
Color Reagent A	895000	1 vial	6 vials	12 mL/vial of stabilized hydrogen peroxide.	
Color Reagent B	895001	1 vial	6 vials	12 mL/vial of stabilized chromogen (tetramethylbenzidine).	
Stop Solution	895032	1 vial	6 vials	6 mL/vial of 2 N sulfuric acid.	
Plate Sealers	N/A	4 strips	24 strips	Adhesive strips.	

* Provided this is within the expiration date of the kit.

D6050 contains sufficient materials to run an ELISA on one 96 well plate.

S6050 (SixPak) contains sufficient materials to run ELISAs on six 96 well plates.

This kit is also available in a PharmPak (R&D Systems, Catalog # PD6050). PharmPaks contain sufficient materials to run ELISAs on 50 microplates. Specific vial counts of each component may vary. Please refer to the literature accompanying your order for specific vial counts.

OTHER SUPPLIES REQUIRED

- Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- Pipettes and pipette tips.
- Deionized or distilled water.
- 500 mL graduated cylinder.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- Test tubes for dilution of standards.
- Human IL-6 Controls (optional; R&D Systems, Catalog # QC01-1).

PRECAUTIONS

Calibrator Diluent RD6F contains sodium azide which may react with lead and copper plumbing to form explosive metallic azides. Flush with large volumes of water during disposal.

The Stop Solution provided with this kit is an acid solution.

Some components in this kit contain a preservative which may cause an allergic skin reaction. Avoid breathing mist.

Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.

Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Please refer to the MSDS on our website prior to use

SAMPLE COLLECTION & STORAGE

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or aliquot and store samples at $\leq -20^{\circ}\text{C}$. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at $\leq -20^{\circ}\text{C}$. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at $\leq -20^{\circ}\text{C}$. Avoid repeated freeze-thaw cycles.

REAGENT PREPARATION


Bring all reagents to room temperature before use.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to deionized or distilled water to prepare 500 mL of Wash Buffer.

Substrate Solution - Color Reagents A and B should be mixed together in equal volumes within 15 minutes of use. Protect from light. 200 μ L of the resultant mixture is required per well.

Human IL-6 Standard - **Refer to the vial label for reconstitution volume.** Reconstitute the Human IL-6 Standard with Calibrator Diluent RD5T (*for cell culture supernate samples*) or Calibrator Diluent RD6F (*for serum/plasma samples*). This reconstitution produces a stock solution of 300 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.

Pipette 667 μ L of the appropriate Calibrator Diluent into the 100 pg/mL tube and 500 μ L of diluent into each remaining tube. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The undiluted standard serves as the high standard (300 pg/mL). The appropriate Calibrator Diluent serves as the zero standard (0 pg/mL).



ASSAY PROCEDURE

Bring all reagents and samples to room temperature before use. It is recommended that all standards, samples, and controls be assayed in duplicate.

1. Prepare all reagents and working standards as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
3. Add 100 μ L of Assay Diluent RD1W to each well.
4. Add 100 μ L of Standard, sample, or control per well. Cover with the adhesive strip provided. Incubate for 2 hours at room temperature. A plate layout is provided to record standards and samples assayed.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (400 μ L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 200 μ L of Human IL-6 Conjugate to each well. Cover with a new adhesive strip. Incubate for 2 hours at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add 200 μ L of Substrate Solution to each well. Incubate for 20 minutes at room temperature. **Protect from light.**
9. Add 50 μ L of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

CALCULATION OF RESULTS

Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.).


Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the human IL-6 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

TYPICAL DATA


These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

CELL CULTURE SUPERNATE ASSAY



(pg/mL)	O.D.	Average	Corrected
0	0.022 0.028	0.025	—
3.13	0.050 0.052	0.051	0.026
6.25	0.078 0.078	0.078	0.053
12.5	0.134 0.136	0.135	0.110
25	0.247 0.245	0.246	0.221
50	0.472 0.465	0.468	0.443
100	0.865 0.836	0.850	0.825
300	2.524 2.515	2.520	2.495

SERUM/PLASMA ASSAY



(pg/mL)	O.D.	Average	Corrected
0	0.025 0.029	0.027	—
3.13	0.049 0.051	0.050	0.023
6.25	0.078 0.077	0.078	0.051
12.5	0.127 0.129	0.128	0.101
25	0.236 0.236	0.236	0.209
50	0.438 0.442	0.440	0.413
100	0.780 0.773	0.776	0.749
300	2.176 2.221	2.198	2.171

PRECISION

Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)

Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

CELL CULTURE SUPERNATE ASSAY

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
Mean (pg/mL)	15.8	95.6	179	16.4	98.8	188
Standard deviation	0.7	3.0	3.1	0.6	2.5	3.7
CV (%)	4.4	3.1	1.7	3.7	2.5	2.0

SERUM/PLASMA ASSAY

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
Mean (pg/mL)	16.8	97.7	186	17.2	101	191
Standard deviation	0.7	1.6	3.8	1.1	3.3	7.2
CV (%)	4.2	1.6	2.0	6.4	3.3	3.8

RECOVERY

The recovery of human IL-6 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % Recovery	Range
Cell culture media (n=5)	98	94-103%
Serum (n=5)	93	86- 99%
EDTA plasma (n=5)	95	84-101%
Heparin plasma (n=5)	90	88-98%
Citrate plasma (n=5)	91	82-95%

SENSITIVITY

The minimum detectable dose (MDD) of human IL-6 is typically less than 0.70 pg/mL.

The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

LINEARITY

To assess the linearity of the assay, samples were spiked with high concentrations of human IL-6 in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.

		Cell culture media (n=4)	Serum (n=4)	EDTA plasma (n=4)	Heparin plasma (n=4)	Citrate plasma (n=4)
1:2	Average % of Expected	99	97	101	103	101
	Range (%)	96-101	92-100	98-105	96-109	96-106
1:4	Average % of Expected	100	101	104	106	105
	Range (%)	93-110	93-107	97-110	97-113	101-109
1:8	Average % of Expected	96	102	100	104	106
	Range (%)	92-100	96-108	86-112	93-111	101-111
1:16	Average % of Expected	94	103	99	105	101
	Range (%)	83-108	93-111	90-110	99-107	90-114

CALIBRATION

This immunoassay is calibrated against highly purified *E. coli*-expressed recombinant human IL-6 produced at R&D Systems. The NIBSC/WHO 1st International Standard for IL-6 (89/548), which was intended as a potency standard, was evaluated in this kit. The NIBSC/WHO standard is a CHO cell-derived recombinant human IL-6.

The dose response curve of the International Standard (89/548) parallels the Quantikine standard curve. To convert sample values obtained with the Quantikine Human IL-6 kit to approximate NIBSC 89/548 units, use the equation below.

NIBSC (89/548) approximate value (IU/mL)=0.131 x Quantikine Human IL-6 value (pg/mL)

SAMPLE VALUES

Serum/Plasma - Forty serum and plasma samples from apparently healthy volunteers were evaluated for the presence of human IL-6 in this assay. Thirty-three samples measured less than the lowest standard, 3.13 pg/mL. Seven samples measured between 3.13 and 12.5 pg/mL. No medical histories were available for the donors used in this study.

Cell Culture Supernates - Human peripheral blood mononuclear cells (1×10^6 cells/mL) were cultured in RPMI supplemented with 10% fetal calf serum, 50 μ M β -mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μ g/mL streptomycin sulfate and stimulated for 1, 3, and 5 days with 10 μ g/mL PHA. Aliquots of the culture supernates were removed on days 1, 3, and 5 and assayed for levels of natural human IL-6. Results are listed in the following table.

Condition	Day 1 (pg/mL)	Day 3 (pg/mL)	Day 5 (pg/mL)
Unstimulated	575	311	660
Stimulated	17,130	17,520	16,340

SPECIFICITY

This assay recognizes natural and recombinant human IL-6.

The factors listed below were prepared at 50 ng/mL in Calibrator Diluent RD5T and at 100 ng/mL in Calibrator Diluent RD6F and assayed for cross-reactivity. Preparations of the following factors at 50 ng/mL in a mid-range rhIL-6 control prepared in Calibrator Diluent RD5T and 100 ng/mL in a mid-range IL-6 control prepared in Calibrator Diluent RD6F were assayed for interference. No significant cross-reactivity or interference was observed.

Recombinant human:

CNTF	IL-7
G-CSF	IL-8
GM-CSF	IL-11
sgp130	IL-12
IL-1 α	LIF
IL-1 β	LIF R
IL-2	OSM
IL-3	TNF- α
IL-4	TNF- β
IL-6 Ra	
IL-6 Ra/sgp130	

Recombinant mouse:



GM-CSF
IL-2
IL-3
IL-4
IL-5
IL-6
IL-7
IL-11
IL-12

Recombinant rat:

CNTF

Natural proteins:

bovine FGF acidic
bovine FGF basic
human PDGF
porcine PDGF
human TGF- β 1
porcine TGF- β 1.2
porcine TGF- β 2



Monocytes were prepared from human PBMCs by adherence to plastic. Adherent monocytes were washed, replated, and allowed to rest for 24 hours. Pretreatments were for 30 minutes: neutralizing anti-human TNF- α (R&D Systems, Catalog # MAB610) at 5 μ g/mL, H7 serine kinase inhibitor (Tocris, Catalog # 0542) at 10 μ M, or HU211 NF κ B inhibitor (Tocris, Catalog # 2861) at 10 μ M. Following the pretreatment, 500 ng/mL LPS or 30 ng/mL okadaic acid (OA, Tocris, Catalog # 1136) was added for 20 hours as indicated. Conditioned media was tested in the Quantikine ELISA, resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the detection antibody used in this kit. The immunoprecipitation/ Western blot shows direct correlation with the ELISA value for these samples.

REFERENCES

1. Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. **24**:249.
2. Schuett, H. *et al.* (2009) Thromb. Haemost. **102**:215.
3. Erta, M. *et al.* (2012) Int. J. Biol. Sci. **8**:1254.
4. Garbers, C. *et al.* (2012) Cytokine Growth Factor Rev. **23**:85.
5. Mihara, M. *et al.* (2012) Clin. Sci. (Lond.) **122**:143.
6. Hirano, T. *et al.* (1986) Nature **324**:73.
7. Kestler, D.P. *et al.* (1995) Blood **86**:4559.
8. Kestler, D.P. *et al.* (1999) Am. J. Hematol. **61**:169.
9. Bihl, M.P. *et al.* (2002) Am. J. Respir. Cell Mol. Biol. **27**:48.
10. Alberti, L. *et al.* (2005) Cancer Res. **65**:2.
11. May, L.T. *et al.* (1986) Proc. Natl. Acad. Sci. USA **83**:8957.
12. Sad, S. *et al.* (1995) Immunity **2**:271.
13. Cichy, J. *et al.* (1996) Biochem. Biophys. Res. Commun. **227**:318.
14. Miyazawa, K. *et al.* (1998) Am. J. Pathol. **152**:793.
15. Fried, S.K. *et al.* (1998) Endocrinology **83**:847.
16. Ishimi, Y. *et al.* (1990) J. Immunol. **145**:3297.
17. Jiang, S. *et al.* (1994) Blood **84**:4151.
18. Xin, X. *et al.* (1995) Endocrinology **136**:132.
19. Marz, P. *et al.* (1998) Proc. Natl. Acad. Sci. USA **95**:3251.
20. Ringheim, G.E. *et al.* (1995) J. Neuroimmunol. **63**:113.
21. Gadiant, R.A. *et al.* (1995) Neurosci. Lett. **194**:17.
22. Kuppner, M.C. *et al.* (1995) Immunology **84**:265.
23. Gagari, E. *et al.* (1997) Blood **89**:2654.
24. Cumberbatch, M. *et al.* (1996) Immunology **87**:513.
25. Fujisawa, H. *et al.* (1997) J. Interferon Cytokine Res. **17**:347.
26. Lee, S.C. *et al.* (1993) J. Immunol. **150**:2659.
27. Lafortune, L. *et al.* (1996) J. Neuropathol. Exp. Neurol. **55**:515.
28. Ericson, S.G. *et al.* (1998) Blood **91**:2099.
29. Melani, C. *et al.* (1993) Blood **81**:2744.
30. Lacy, P. *et al.* (1998) Blood **91**:2508.
31. Jung, H.C. *et al.* (1995) J. Clin. Invest. **95**:55.
32. Spencer, N.F.L. and R.A. Daynes (1997) Int. Immunol. **9**:745.
33. Campbell, I.L. *et al.* (1989) J. Immunol. **143**:1188.
34. D'Auria, L. *et al.* (1997) Eur. Cytokine Netw. **8**:383.
35. Yamamura, M. *et al.* (1998) Br. J. Haematol. **100**:129.
36. Angstwurm, M.W.A. *et al.* (1997) Cytokine **9**:370.
37. Mouawad, R. *et al.* (1996) Clin. Cancer Res. **2**:1405.
38. Sakamoto, K. *et al.* (1994) Cytokine **6**:181.
39. Murakami, M. *et al.* (1993) Science **260**:1808.
40. Muller-Newen, G. (2003) Sci. STKE **2003**:PE40.
41. Mitsuyama, K. *et al.* (2006) Clin. Exp. Immunol. **143**:125.
42. Cerutti, A. *et al.* (1998) J. Immunol. **160**:2145.

PLATE LAYOUT

Use this plate layout to record standards and samples assayed.

12								
11								
10								
9								
8								
7								
6								
5								
4								
3								
2								
1								
	A	B	C	D	E	F	G	H

